Most Read Articles
Audrey Abella, 07 Nov 2019
Cognitive behavioural therapy (CBT) may improve symptoms of irritable bowel syndrome (IBS), according to the follow-up results of the ACTIB* trial.
17 Nov 2019
Distance-based interventions to assist smoking cessation (SC) appear to be effective among cancer survivors, reports a recent meta-analysis.
19 Nov 2019
Women with post-traumatic stress disorder (PTSD) are at increased risk of developing thyroid dysfunction, a study reports.
06 Nov 2019
No consistent superior cost-effectiveness has been observed in either second-generation antidepressants (SGAs) or cognitive behavioural therapy (CBT) when compared to the other, according to a study.

Sodium benzoate augments clozapine for schizophrenia

10 Feb 2018
The second generation injection may cost up to HK$5000 per month.

Sodium benzoate appears to augment the effects of clozapine, according to a recent study, which shows that the combination therapy results in significant improvements in symptomatology in clozapine-resistant schizophrenia patients.

The randomized, double-blind, placebo-controlled trial included 60 schizophrenia patients stabilized with clozapine who were randomized to receive one of three add-on treatments: 1 g/day of sodium benzoate (n=20), 2 g/day of sodium benzoate (n=20) or placebo (n=20). Add-on treatment was administered for an additional 60 days.

Both doses of sodium benzoate yielded significantly greater changes from baseline in the Scales for the Assessment of Negative Symptoms (SANS-20) scores relative to placebo at 6 weeks (p=0.029 for 1 g; p=0.031 for 2 g).

In comparison, only the 2-g sodium benzoate treatment resulted in significant 6-week improvements in the Positive and Negative Syndrome Scale (PANSS) scores compared with placebo (p=0.006).

Scores in the quality of life scale were also significantly better in the 2-g sodium benzoate vs placebo group at 6 weeks (p=0.009). No such effect was observed with 1 g of the add-on treatment.

In terms of secondary outcomes, neither 1 g or 2 g of add-on sodium benzoate resulted in significant 6-week improvements in depression, as per the Hamilton rating scale for depression (p=0.729 and p=0.114, respectively), and endpoint improvements in cognitive function (p=0.185 and p=0.930, respectively).

Minimal extrapyramidal syndrome was reported in all three groups both at baseline and at the conclusion of the study.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 07 Nov 2019
Cognitive behavioural therapy (CBT) may improve symptoms of irritable bowel syndrome (IBS), according to the follow-up results of the ACTIB* trial.
17 Nov 2019
Distance-based interventions to assist smoking cessation (SC) appear to be effective among cancer survivors, reports a recent meta-analysis.
19 Nov 2019
Women with post-traumatic stress disorder (PTSD) are at increased risk of developing thyroid dysfunction, a study reports.
06 Nov 2019
No consistent superior cost-effectiveness has been observed in either second-generation antidepressants (SGAs) or cognitive behavioural therapy (CBT) when compared to the other, according to a study.